Trials / Conditions / Recurrent Angioimmunoblastic T-Cell Lymphoma
Recurrent Angioimmunoblastic T-Cell Lymphoma
6 registered clinical trials studyying Recurrent Angioimmunoblastic T-Cell Lymphoma — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Withdrawn | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma NCT04795869 | Northwestern University | Phase 2 |
| Active Not Recruiting | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas NCT03598998 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) in Combination With Romidepsin NCT03278782 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma NCT03075553 | Mayo Clinic | Phase 2 |
| Recruiting | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemi NCT03017820 | Mayo Clinic | Phase 1 |
| Completed | Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Periph NCT01590732 | M.D. Anderson Cancer Center | Phase 1 |